BioGend Therapeutics Statistics

Total Valuation

TPEX:6733 has a market cap or net worth of TWD 4.46 billion. The enterprise value is 3.96 billion.

Market Cap	4.46B
Enterprise Value	3.96B

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

TPEX:6733 has 124.36 million shares outstanding. The number of shares has decreased by -0.37% in one year.

Current Share Class	124.36M
Shares Outstanding	124.36M
Shares Change (YoY)	-0.37%
Shares Change (QoQ)	-1.47%
Owned by Insiders (%)	4.20%
Owned by Institutions (%)	2.56%
Float	75.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	20.05
PB Ratio	5.88
P/TBV Ratio	6.84
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-46.83
EV / Sales	17.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-60.48

Financial Position

The company has a current ratio of 17.60, with a Debt / Equity ratio of 0.01.

Current Ratio	17.60
Quick Ratio	16.02
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-731.75

Financial Efficiency

Return on equity (ROE) is -11.88% and return on invested capital (ROIC) is -8.53%.

Return on Equity (ROE)	-11.88%
Return on Assets (ROA)	-7.99%
Return on Invested Capital (ROIC)	-8.53%
Return on Capital Employed (ROCE)	-14.18%
Weighted Average Cost of Capital (WACC)	5.31%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.26
Inventory Turnover	3.41

Taxes

Income Tax	-8.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.02% in the last 52 weeks. The beta is 0.19, so TPEX:6733's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	+7.02%
50-Day Moving Average	37.73
200-Day Moving Average	36.49
Relative Strength Index (RSI)	39.16
Average Volume (20 Days)	217,958

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6733 had revenue of TWD 222.34 million and -84.61 million in losses. Loss per share was -0.69.

Revenue	222.34M
Gross Profit	160.16M
Operating Income	-110.50M
Pretax Income	-103.61M
Net Income	-84.61M
EBITDA	-60.73M
EBIT	-110.50M
Loss Per Share	-0.69

Full Income Statement

Balance Sheet

The company has 517.90 million in cash and 6.58 million in debt, giving a net cash position of 511.33 million or 4.11 per share.

Cash & Cash Equivalents	517.90M
Total Debt	6.58M
Net Cash	511.33M
Net Cash Per Share	4.11
Equity (Book Value)	757.64M
Book Value Per Share	6.12
Working Capital	600.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -63.66 million and capital expenditures -1.87 million, giving a free cash flow of -65.52 million.

Operating Cash Flow	-63.66M
Capital Expenditures	-1.87M
Free Cash Flow	-65.52M
FCF Per Share	-0.53

Full Cash Flow Statement

Margins

Gross margin is 72.03%, with operating and profit margins of -49.70% and -38.05%.

Gross Margin	72.03%
Operating Margin	-49.70%
Pretax Margin	-46.60%
Profit Margin	-38.05%
EBITDA Margin	-27.31%
EBIT Margin	-49.70%
FCF Margin	n/a

Dividends & Yields

TPEX:6733 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.37%
Shareholder Yield	0.37%
Earnings Yield	-1.90%
FCF Yield	-1.47%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6733 has an Altman Z-Score of 44.69 and a Piotroski F-Score of 2.

Altman Z-Score	44.69
Piotroski F-Score	2